Chemistry:Eglumegad

From HandWiki
Eglumegad
Eglumegad.svg
Clinical data
ATC code
  • none
Identifiers
CAS Number
PubChem CID
IUPHAR/BPS
ChemSpider
UNII
Chemical and physical data
FormulaC8H11NO4
Molar mass185.179 g·mol−1
3D model (JSmol)
 ☒N☑Y (what is this?)  (verify)

Eglumegad (LY354740) is a research drug developed by Eli Lilly and Company, which is being investigated for its potential in the treatment of anxiety[1] and drug addiction.[2] It is a glutamate derived compound and its mode of action implies a novel mechanism.[3]

Mechanism of action

Eglumegad acts as a group-selective agonist for the group II metabotropic glutamate receptors (mGluR2/3).[4][5] It is unclear whether eglumegad directly interacts with dopamine D2 receptors.[6][7]

Effects

In experiments on mice, eglumegad was found to be as effective as diazepam for treating anxiety symptoms in several standard tests, but without producing any of the negative side effects of diazepam such as sedation and memory impairment.[8] Tests in humans confirmed that it produced anxiolytic effects without producing sedation.[9][10] However it did slightly reduce cognitive performance in tests on monkeys.[11]

Eglumegad has also been found to be effective in relieving the symptoms of withdrawal from chronic use of both nicotine[12] and morphine in animals,[13] as well as inhibiting the development of tolerance to morphine,[14] raising hope that this drug may be useful for treating drug addiction in humans.

Eglumegad and related drugs are neuroprotective[15] and are synergistic with the neuroprotection produced by N-methyl-D-aspartic acid (NMDA) antagonist drugs,[16] which may make these drugs useful in aiding recovery from brain injury.

This class of drugs also interacts with hallucinogenic drugs, with eglumegad reducing the effects of 5HT2A agonist hallucinogens,[17] while conversely the mGluR2/3 antagonist LY341495 increased the behavioural effects of these drugs.[18] This suggests that mGluR2/3 agonists such as eglumegad may have potential uses in the treatment of some forms of psychosis, although eglumegad had only limited effects on the action of the dissociative drug phencyclidine[19] which is generally a better model for schizophrenia than the 5HT2A agonist hallucinogens.[20]

Eglumegad also interferes in the hypothalamic–pituitary–adrenal axis, with chronic oral administration of this drug leading to markedly reduced baseline cortisol levels in bonnet macaques (Macaca radiata); acute infusion of eglumegad resulted in a marked diminution of yohimbine-induced stress response in those animals.[21]

In human adrenocortical cells, eglumegad has been shown to down-regulate intracellular cyclic AMP (cAMP) and steroidogenesis, with a significant decrease in aldosterone and cortisol production.[22]

Clinical development

Development of this drug and related compounds is continuing, with several clinical trials completed and more planned. Poor oral bioavailability of the original formulation led to limited efficacy in the initial human trials,[23] and so the prodrug form LY544344 did seem to be a more likely drug candidate for further development.[24][25][26][27] However a clinical trial of LY544344 was discontinued early based on findings of convulsions in preclinical studies.[28]

LY-544,344

See also

References

  1. ↑ Pilc A (January 2003). "LY-354740 (Eli Lilly)". IDrugs 6 (1): 66–71. PMID 12789623. 
  2. ↑ "Potential anti-anxiety, anti-addictive effects of LY 354740, a selective group II glutamate metabotropic receptors agonist in animal models". Neuropharmacology 38 (12): 1831–9. December 1999. doi:10.1016/S0028-3908(99)00066-0. PMID 10608278. 
  3. ↑ "Design, synthesis, and pharmacological characterization of (+)-2-aminobicyclo[3.1.0]hexane-2,6-dicarboxylic acid (LY354740): a potent, selective, and orally active group 2 metabotropic glutamate receptor agonist possessing anticonvulsant and anxiolytic properties". J. Med. Chem. 40 (4): 528–37. February 1997. doi:10.1021/jm9606756. PMID 9046344. 
  4. ↑ "LY354740 is a potent and highly selective group II metabotropic glutamate receptor agonist in cells expressing human glutamate receptors". Neuropharmacology 36 (1): 1–11. January 1997. doi:10.1016/S0028-3908(96)00160-8. PMID 9144636. 
  5. ↑ "A novel orally active group 2 metabotropic glutamate receptor agonist: LY354740". NeuroReport 8 (6): 1463–6. April 1997. doi:10.1097/00001756-199704140-00027. PMID 9172154. 
  6. ↑ "Dopamine partial agonist actions of the glutamate receptor agonists LY 354,740 and LY 379,268". Synapse 62 (2): 154–8. February 2008. doi:10.1002/syn.20482. PMID 18000815. 
  7. ↑ "In vitro and in vivo evidence for a lack of interaction with dopamine D2 receptors by the metabotropic glutamate 2/3 receptor agonists 1S,2S,5R,6S-2-aminobicyclo[3.1.0]hexane-2,6-bicaroxylate monohydrate (LY354740) and (−)-2-oxa-4-aminobicyclo[3.1.0] Hexane-4,6-dicarboxylic acid (LY379268)". J. Pharmacol. Exp. Ther. 331 (3): 1126–36. December 2009. doi:10.1124/jpet.109.160598. PMID 19755662. 
  8. ↑ "Anxiolytic and side-effect profile of LY354740: a potent, highly selective, orally active agonist for group II metabotropic glutamate receptors". J. Pharmacol. Exp. Ther. 284 (2): 651–60. February 1998. PMID 9454811. 
  9. ↑ "Anxiolytic effects of a novel group II metabotropic glutamate receptor agonist (LY354740) in the fear-potentiated startle paradigm in humans". Psychopharmacology 168 (4): 446–54. August 2003. doi:10.1007/s00213-003-1444-8. PMID 12709777. https://zenodo.org/record/1232619. 
  10. ↑ "LY354740, an mGlu2/3 receptor agonist as a novel approach to treat anxiety/stress". Stress 6 (3): 189–97. September 2003. doi:10.1080/1025389031000146773. PMID 13129812. 
  11. ↑ "Effects of the mGluR2/3 agonist LY354740 on computerized tasks of attention and working memory in marmoset monkeys". Psychopharmacology 179 (1): 292–302. April 2005. doi:10.1007/s00213-004-2126-x. PMID 15678362. http://doc.rero.ch/record/310361/files/213_2004_Article_2126.pdf. 
  12. ↑ "LY354740: a metabotropic glutamate receptor agonist which ameliorates symptoms of nicotine withdrawal in rats". Neuropharmacology 36 (11–12): 1511–6. 1997. doi:10.1016/S0028-3908(97)00170-6. PMID 9517421. 
  13. ↑ "The selective mGlu2/3 receptor agonist LY354740 attenuates morphine-withdrawal-induced activation of locus coeruleus neurons and behavioral signs of morphine withdrawal". Neuropharmacology 38 (2): 217–22. February 1999. doi:10.1016/S0028-3908(98)00196-8. PMID 10218862. 
  14. ↑ "Selective agonist of group II glutamate metabotropic receptors, LY354740, inhibits tolerance to analgesic effects of morphine in mice". Br. J. Pharmacol. 130 (6): 1425–31. July 2000. doi:10.1038/sj.bjp.0703438. PMID 10903986. 
  15. ↑ "Neuroprotection by metabotropic glutamate receptor glutamate receptor agonists: LY354740, LY379268 and LY389795". Eur. J. Pharmacol. 377 (2–3): 155–65. July 1999. doi:10.1016/S0014-2999(99)00397-0. PMID 10456425. 
  16. ↑ "Group II metabotropic glutamate receptor activation attenuates traumatic neuronal injury and improves neurological recovery after traumatic brain injury". J. Pharmacol. Exp. Ther. 290 (1): 112–20. July 1999. PMID 10381766. 
  17. ↑ "Physiological antagonism between 5-hydroxytryptamine(2A) and group II metabotropic glutamate receptors in prefrontal cortex". J. Pharmacol. Exp. Ther. 292 (1): 76–87. January 2000. PMID 10604933. 
  18. ↑ "Behavioral evidence for interactions between a hallucinogenic drug and group II metabotropic glutamate receptors". Neuropsychopharmacology 23 (5): 569–76. November 2000. doi:10.1016/S0893-133X(00)00136-6. PMID 11027922. 
  19. ↑ "LY354740 affects startle responding but not sensorimotor gating or discriminative effects of phencyclidine". Eur. J. Pharmacol. 388 (2): R3–4. January 2000. doi:10.1016/S0014-2999(99)00844-4. PMID 10666513. 
  20. ↑ "Preclinical pharmacology of mGlu2/3 receptor agonists: novel agents for schizophrenia?". Curr Drug Targets CNS Neurol Disord 1 (2): 215–25. April 2002. doi:10.2174/1568007024606177. PMID 12769628. 
  21. ↑ "Effects of LY354740, a novel glutamatergic metabotropic agonist, on nonhuman primate hypothalamic-pituitary-adrenal axis and noradrenergic function". CNS Spectr 6 (7): 607–12, 617. July 2001. doi:10.1017/S1092852900002157. PMID 15573025. 
  22. ↑ "Glutamate Receptors and the Regulation of Steroidogenesis in the Human Adrenal Gland: The Metabotropic Pathway". Molecular and Cellular Endocrinology 382 (1): 170–7. January 2014. doi:10.1016/j.mce.2013.09.025. PMID 24080311. 
  23. ↑ "Metabotropic glutamate II receptor agonists in panic disorder: a double blind clinical trial with LY354740". Int Clin Psychopharmacol 20 (6): 291–3. November 2005. doi:10.1097/00004850-200511000-00001. PMID 16192835. 
  24. ↑ "Dipeptides as effective prodrugs of the unnatural amino acid (+)-2-aminobicyclo[3.1.0]hexane-2,6-dicarboxylic acid (LY354740), a selective group II metabotropic glutamate receptor agonist". J. Med. Chem. 48 (16): 5305–20. August 2005. doi:10.1021/jm050235r. PMID 16078848. 
  25. ↑ "Improved bioavailability of the mGlu2/3 receptor agonist LY354740 using a prodrug strategy: in vivo pharmacology of LY544344". J. Pharmacol. Exp. Ther. 316 (2): 905–13. February 2006. doi:10.1124/jpet.105.091926. PMID 16223873. 
  26. ↑ Danysz W (September 2005). "LY-544344. Eli Lilly". IDrugs 8 (9): 755–62. PMID 16118698. 
  27. ↑ "Pharmacokinetics, metabolism, and excretion of the intestinal peptide transporter 1 (SLC15A1)-targeted prodrug (1S,2S,5R,6S)-2-[(2'S)-(2-amino)propionyl]aminobicyclo[3.1.0.]hexen-2,6-dicarboxylic acid (LY544344) in rats and dogs: assessment of first-pass bioactivation and dose linearity". Drug Metab. Dispos. 35 (10): 1903–9. October 2007. doi:10.1124/dmd.107.016154. PMID 17646281. 
  28. ↑ "Efficacy and tolerability of an mGlu2/3 agonist in the treatment of generalized anxiety disorder". Neuropsychopharmacology 33 (7): 1603–10. June 2008. doi:10.1038/sj.npp.1301531. PMID 17712352. 




Retrieved from "https://handwiki.org/wiki/index.php?title=Chemistry:Eglumegad&oldid=3421012"